Spero Therapeutics, Inc. (SPRO) Bundle
An Overview of Spero Therapeutics, Inc. (SPRO)
General Summary of Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for infectious diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts.
Company Products and Services
Key product portfolio includes:
- ENVARSUS XR (tacrolimus extended-release tablets)
- SPR206 (novel anti-infective agent)
- Tebipenem pivoxil (oral carbapenem antibiotic)
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $41.4 million |
| Net Loss | $94.5 million |
| Cash and Investments | $185.3 million |
Market Position
Key Market Strengths:
- Focused on critical unmet medical needs in infectious diseases
- Advanced pipeline of novel antimicrobial therapies
- Robust research and development capabilities
Company Highlights
| Metric | 2024 Status |
|---|---|
| Research Programs | 4 active clinical development programs |
| Patent Portfolio | 23 issued patents |
| Employee Count | Approximately 180 employees |
Mission Statement of Spero Therapeutics, Inc. (SPRO)
Mission Statement of Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO) mission statement focuses on developing innovative antibiotic therapies to address critical unmet medical needs in infectious disease treatment.
Key Mission Components
| Research Focus | Gram-negative bacterial infections |
| Primary Pipeline Target | Rare and difficult-to-treat bacterial infections |
| Annual R&D Investment | $45.2 million (2023 fiscal year) |
Strategic Mission Objectives
- Develop novel antibiotic therapies targeting drug-resistant bacterial infections
- Advance proprietary platform technologies for enhanced treatment options
- Address critical gaps in infectious disease management
Research and Development Metrics
| Active Clinical Trials | 5 ongoing clinical programs |
| Patent Portfolio | 23 granted patents |
| Research Collaboration Agreements | 3 active pharmaceutical partnerships |
Therapeutic Portfolio Focus
Key Therapeutic Areas:
- Rare bacterial infections
- Multi-drug resistant bacterial strains
- Hospital-acquired bacterial infections
Financial Commitment to Mission
| Total Research Budget 2024 | $52.7 million |
| Percentage of Revenue Reinvested | 68% in R&D |
| Current Cash Position | $187.3 million (Q4 2023) |
Vision Statement of Spero Therapeutics, Inc. (SPRO)
Vision Statement Components of Spero Therapeutics, Inc. (SPRO)
Strategic Vision FrameworkSpero Therapeutics, Inc. reported Q4 2023 revenue of $18.9 million, focusing on developing innovative therapies for infectious diseases and oncology.
Core Vision Elements
Infectious Disease InnovationAs of 2024, Spero Therapeutics targets the development of novel antibiotics targeting multi-drug resistant bacterial infections.
| Research Focus | Current Pipeline Status | Development Stage |
|---|---|---|
| Tebipenem HBr | Phase 3 Clinical Trials | Oral Carbapenem Antibiotic |
| SPR206 | Preclinical Development | Gram-Negative Bacterial Infections |
Oncology Research Objectives
Targeted Therapeutic ApproachSpero Therapeutics maintains an oncology research platform with specific focus areas:
- Precision immunotherapy development
- Novel mechanism of action research
- Combination therapeutic strategies
Financial Investment in Research
R&D ExpenditureFor fiscal year 2023, Spero Therapeutics invested $95.4 million in research and development activities.
| Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2023 | $95.4 million | 82.3% |
| 2022 | $88.7 million | 79.6% |
Strategic Partnership Landscape
Collaborative Research InitiativesSpero Therapeutics maintains strategic collaborations with multiple research institutions and pharmaceutical companies.
- Collaboration with GARDP Foundation
- Partnership with academic research centers
- Ongoing clinical trial network engagement
Core Values of Spero Therapeutics, Inc. (SPRO)
Core Values of Spero Therapeutics, Inc. (SPRO) in 2024
Innovation and Scientific ExcellenceSpero Therapeutics demonstrates commitment to innovation through its research and development efforts in antimicrobial therapeutics.
| R&D Investment | 2023 Amount |
|---|---|
| Total R&D Expenses | $66.4 million |
| Research Pipeline Programs | 5 active programs |
- Developing novel antibiotic therapies
- Advancing SPR206 for multi-drug resistant infections
- Pursuing breakthrough antimicrobial technologies
Spero Therapeutics focuses on addressing critical unmet medical needs in infectious diseases.
| Patient Impact Metrics | 2023 Data |
|---|---|
| Clinical Trial Participants | 387 patients |
| Target Patient Populations | Multi-drug resistant infections |
The company emphasizes strategic partnerships and collaborative research efforts.
- Partnerships with academic institutions
- Collaborative research agreements
- NIH and government research grants
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.2 million |
| Cash and Investments | $146.5 million |
| Operating Expenses | $93.7 million |
Spero Therapeutics maintains rigorous ethical standards in pharmaceutical research and development.
- Adherence to FDA clinical trial regulations
- Comprehensive patient safety protocols
- Transparent reporting of research outcomes
| Sustainability Metric | 2023 Performance |
|---|---|
| Corporate Headcount | 134 employees |
| Research Facilities | 2 primary locations |
Spero Therapeutics, Inc. (SPRO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.